Mark Cusworth, vice president of R&D at PRISYM ID looks at how labelling can improve patient retention in clinical trials.
Surprise package
As global healthcare grapples the problem of medicines adherence, C. Everett Koop’s famous observation has become a familiar retort: “drugs don’t work in patients who don’t take them.” The same concept applies in clinical studies. Trials don’t work when patients don’t take their meds. What’s more, if the cost of recruiting patients to clinical studies is high, the price of failing to keep them there is even higher.